| |
All Patients
|
Trimetazidine
|
Placebo
|
|---|
|
Mean age (years)
|
65.4 ± 6.3
|
65.6 ± 5.7
|
65.2 ± 7
|
|
Male
|
24
|
11
|
13
|
|
Female
|
8
|
5
|
3
|
|
BMI
|
25.4 ± 3.2
|
25.7 ± 3.3
|
25.2 ± 3.3
|
|
Baseline glucose
|
164.6 ± 26.2
|
166.9 ± 21.9
|
162.2 ± 30.4
|
|
Triglycerides at baseline
|
238.1 ± 59.5
|
231.3 ± 43.7
|
244.9 ± 72.9
|
|
Triglycerides at randomisation
|
185.7 ± 46.4
|
180.5 ± 34
|
191 ± 57
|
|
Cholesterol at baseline
|
264.5 ± 27.8
|
263.3 ± 29.3
|
265.2 ± 27.2
|
|
Cholesterol at randomisation
|
198.3 ± 20.8
|
197.8 ± 21.9
|
198.8 ± 20.4
|
|
HBA1c
|
7.6 ± 0.8
|
7.7 ± 1
|
7.5 ± 0.6
|
|
Prior MI
|
18
|
9
|
9
|
|
Prior CABG
|
7
|
4
|
3
|
|
Prior PTCA
|
12
|
6
|
8
|
|
Carotid Atherosclerosis
|
12
|
7
|
5
|
|
Coronary atherosclerosis
| | | |
|
1 vessel disease
|
1
|
0
|
1
|
|
2 vessel disease
|
14
|
6
|
8
|
|
3 vessel disease
|
16
|
9
|
7
|
|
any vessel + graft
|
1
|
1
|
0
|
|
distal disease
|
23
|
12
|
11
|
|
USE OF DRUGS AT RANDOMISATION
| | | |
|
Aspirin/ticlopidine
|
18
|
12
|
14
|
|
Clopidogrel
|
6
|
6
|
4
|
|
Anticoagulants
|
6
|
5
|
6
|
|
Digitalis
|
28
|
13
|
15
|
|
Diuretics
|
31
|
16
|
15
|
|
Nitrates
|
18
|
8
|
10
|
|
B-blockers
|
23
|
11
|
12
|
|
Ca-antagonists
|
14
|
9
|
6
|
|
ACE-I
|
29
|
14
|
15
|
|
ARB
|
4
|
2
|
2
|
|
Statins
|
30
|
14
|
16
|
|
Oral hypoglycaemics
|
25
|
12
|
13
|
|
Insulin
|
7
|
4
|
3
|
- Clinical features of study patients. Clinical characteristics, incidence of previous myocardial infarction or revascularization procedures in patients randomized to trimetazidine or placebo. No significant differences were detected between groups. BMI = body mass index, MI = myocardial infarction, CABG = coronary artery by-pass grafting, PC I = percutaneous coronary interventions.
